Phase I-II RTOG Study (99-06) of Patients With Muscle-Invasive Bladder Cancer Undergoing Transurethral Surgery, Paclitaxel, Cisplatin, and Twice-daily Radiotherapy Followed by Selective Bladder Preservation or Radical Cystectomy and Adjuvant Chemotherapy

Urology

Volumn 73, Issue 4, 2009, Pages 833-837

  Kaufman, Donald S ^a   Winter, Kathryn A ^b   Shipley, William U ^a   Heney, Niall M ^a   Wallace III, H James ^c   Toonkel, Leonard M ^d   Zietman, Anthony L ^a   Tanguay, Simon ^f   Sandler, Howard M ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CREATININE; GEMCITABINE; NITROGEN; PACLITAXEL; UREA;

ADULT; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; BLADDER DISEASE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CHRONOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYSTECTOMY; CYTOLYSIS; DISEASE SEVERITY; DISTANT METASTASIS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HIP PAIN; HUMAN; HUMAN TISSUE; HYPONATREMIA; LEUKOPENIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE METASTASIS; NEUTROPENIA; ORGAN PRESERVATION; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION SAFETY; SIDE EFFECT; STROKE; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; URINARY TRACT DISEASE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; CYSTECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SMOOTH; NEOPLASM INVASIVENESS; PACLITAXEL; URETHRA; URINARY BLADDER NEOPLASMS; UROLOGIC SURGICAL PROCEDURES;

EID: 63149142104     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.09.036     Document Type: Article

References (15)

1. Tester W., Porter A., Asbell S., et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocols 85-12. Int J Radiat Oncol Biol Phys 25 (1993) 783-790
2. Tester W., Caplan R., Heaney J., et al. Neoadjuvant combined modality therapy with possible organ preservation for invasive bladder cancer. J Clin Oncol 14 (1996) 119-126
3. Shipley W.U., Winter K.A., Kaufman D.S., et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16 (1998) 3576-3583
4. Kaufman D.S., Winter K.A., Shipley W.U., et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I-II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective preservation or cystectomy depending on the initial response. Oncologist 5 (2000) 471-476
5. Hagan M.P., Winter K.A., Kaufman D.S., et al. RTOG 97-06: initial report of a phase I/II trial of selective bladder-conservation employing TURB, twice-daily accelerated irradiation sensitized with cisplatin followed by adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57 (2003) 665-672
6. MacDougal W.S., Shipley W.U., Kaufman D.S., et al. Cancer of the bladder, ureter and renal pelvis. In: DeVita Jr. V.T., Lawrence T.S., and Rosenberg S.A. (Eds). Cancer: Principles and Practice of Oncology (2008), Lippincott/Williams & Wilkins, Philadelphia 1358-1374
7. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18 (2000) 3068-3077
8. der Bellmunt J.V., Maase H., Mead G.M., et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy: EORTC 30987/Intergroup study. 2007 ASCO Annual Meeting Proceedings, Abstract BA5030. J Clin Oncol 25 suppl (2007) 242S
9. Kaufman D.S., Raghavan D., Carducci M., et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 16 (2000) 1921-1927
10. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Stat Assoc 53 (1958) 457-481
11. Kalbfleisch J.D., and Prentice R.L. The Statistical Analysis of Failure Time Data (1980), John Wiley & Sons, New York
12. Jeter M.D., Janne P.A., Brooks S., et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 53 (2002) 394-400
13. Zietman A.L., Sacco D., Skowronski U., et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamics and quality of life study on long-term survivors. J Urol 170 (2003) 168-174
14. Rodel C., Grabenbauer G.G., Kuhn R., et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20 (2002) 3061-3071
15. Zietman A.L., Shipley W.U., Kaufman D.S., et al. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily irradiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol 160 (1998) 1673-1677